Evaluation of the effectiveness of complementary therapy with Portulaca oleracea capsule on the clinical symptoms of outpatients with COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190303042889N1

Enrollment

Registered

2021-03-30

Start date

2021-05-05

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: Receive common treatments and 300 mg of Portulaca Oleracea extract capsules 2 times a day for 7 days. Intervention 2: Control group: Receive common treatments and p

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Outpatient with COVID-19 Age 18-60 years Patient satisfaction Being alert and lacking organ damage Confirmation of RT-PCR test for SARS-CoV-2 Blood saturated oxygen content more than 90%

Exclusion criteria

Exclusion criteria: Pregnant and lactating women comorbidity End stage Patient

Design outcomes

Primary

Measure	Time frame
Improvement time of clinical manifestation based on questionnaire. Timepoint: The beginning of the intervention & day 14. Method of measurement: questionnaire.;Normalization of CRP and lymphopenia. Timepoint: The beginning of the intervention & day 14. Method of measurement: laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Zhahra HabibianNejad

Mashhad University of Medical Sciences

Habibiannezhadz971@mums.ac.ir98 51 38049

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026